← Eichor
Study identifier: NCT07470593 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Glucose Tolerance Abnormalities Using Continuous Glucose Monitoring for the Identification of Early Loss of Pancreatic Islet Graft Function.

Condition: Type 1 Diabetes (T1D)  ·  Sponsor: University Hospital, Strasbourg, France

PhaseN/A
Planned participants36
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Islet transplantation is associated with drastically improvement glucose control in people with type 1 diabetes. This treatment resulted in the disappearance of severe hypoglycemic events. However, its long-term effectiveness is limited by progressive loss of graft function. Currently, there is no standardized method to detect early dysfunction of the transplanted islets. This study aims to determine whether a parameter derived from continuous glucose monitoring (CGM), Time in Tight Range (70-140 mg/dL), is associated with pancreatic islet grafts function. The study hypothesis is that a decrease in Time in Tight Range reflects early loss of islet graft function.

This description comes directly from the study's public registry record.

Talk to the study team

Pargol ZANDYAZDI  ·  0033 3 88 11 54 30  ·  pargol.zandyazdi@chru-strasbourg.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hopitaux Universitaires de StrasbourgStrasbourg, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07470593